Asana Medical, Inc. to Exhibit at Gold Coast Venture Capital Association 2015 Expo on February 24th

43North's 2014 Business Competition Finalist to Present Its Drug-Free, Non-Surgical Solution for Sufferers of Ulcerative Colitis


MIAMI LAKES, FL--(Marketwired - Feb 12, 2015) - Asana Medical, Inc., ("Asana", the "Company") an early stage medical device company focused on the development and commercialization of its innovative engineered tissue therapy for ulcerative colitis ("UC"), is pleased to announce that they will be exhibiting at the Gold Coast Venture Capital Association ("GCVCA") 2015 Expo in Boca Raton, Florida on February 24th. Chief Executive Officer Marc Ramer will represent Asana Medical at the Expo.

Approximately 5.7 million people worldwide suffer from ulcerative colitis, a disease characterized by recurring episodes of inflammation of the colon lining (mucosa). Typical UC symptoms include pain, chronic diarrhea, bleeding, and urgency to use the restroom. More severe symptoms include malnutrition, stunted growth (in pediatric cases), and a greatly increased risk of colon cancer. There is no known cure for ulcerative colitis. 

Asana Medical, Inc. is currently focusing its resources on the development of a device to treat UC. The Company's solution is to leverage extracellular matrix, a proven tissue engineering technology, to the gastrointestinal space. This technology has been commercialized for over a decade and has been safely used in many clinical applications to treat millions of patients. 

Asana is confident that its unique engineered tissue material, ExtraCellular Matrix Hydrogel (ECMH), can be used to coat and protect the colon in ulcerative colitis patients, allowing the body to heal the inflamed tissue. Asana's device offers a drug-free, surgery-free alternative on a proven and safe therapy that targets the multi-billion dollar ulcerative colitis market.

In November 2014, Asana Medical was awarded $250,000 as one of eleven finalists in 43North's Business Plan Competition. The competition, held in Buffalo, NY, attracted 6,932 entrants from around the world. 

To stay informed on all Asana Medical, Inc. developments and news, join our social communities on Facebook and Twitter or sign up for email alerts at www.asanamedical.com/contact-us.

ABOUT GCVCA EXPO 2015
The GCVCA's Expo 2015 will be held at the Embassy Suites in Boca Raton and will feature approximately 70 exhibitors, half of which will be start-ups and early stage companies from throughout the state of Florida and beyond while the other half will be corporate sponsors of relevance to the regional entrepreneurial community. Organizers expect 600-1,000 investors, entrepreneurs and premium service providers to attend. In addition to the exposition, EXPO 2015 will feature two panels on topics of interest to entrepreneurs and investors alike. For more information, visit http://www.gcvcaexpo.org.

ABOUT ASANA MEDICAL, INC.
Asana Medical is a development-stage medical device company developing a tissue-engineered therapy for the treatment of ulcerative colitis (UC), a debilitating gastrointestinal disease. The Company's therapy, a novel application of a proven technology, will be a first-in-class therapy for the 5.7 million worldwide patients suffering from UC. This therapy will be positioned to compete in a multi-billion dollar market dominated by drug therapies that can have severe side effects. Additionally, 20-30% of patients do not benefit from drug therapy and have no alternative except colon removal surgery. Asana counts on an experienced management team, strong IP, world-class advisors in business and medicine, and compelling preclinical proof-of-concept data. For more information, visit www.asanamedical.com.

Contact Information:

Company contact:

Marc Ramer
CEO
Asana Medical, Inc.
Tel: (844) 432-7262 ext. 103
6135 NW 167 Street, Suite E15
Miami Lakes, FL 33015
Email: